# US 2013/0251689 A1 · Keratin compositions for treatment of bone deficiency or injury

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0251689 A1
- Document ID: US20130251689A1
- Status: Published application
- Kind: A1
- Application number: 13/895,485
- Filed: 2013-05-16
- Published: 2013-09-26
- Earliest claimed: 2010-11-17
- Assignees: Wake Forest University Health Sciences
- Applicants: Wake Forest University Health Sciences
- Inventors: Mark E. Van Dyke; Thaleia Teli
- Web page: https://patentgrep.com/patent/US20130251689A1

## CPC

- A61K 38/1748: {Keratin; Cytokeratin}
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 38/1875: {Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor}
- A61K 38/39: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A61L 27/227: {Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24}
- A61L 27/44: having a macromolecular matrix
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61L 2300/406: Antibiotics
- A61L 2430/02: for reconstruction of bones; weight-bearing implants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A bone graft composition is described, with one or more of: (a) keratose; (b) kerateine; (c) optionally, particulate filler; (d) optionally, an antibiotic; and (e) water or saline. The composition may be provided in sterile form in a container, and optionally lyophilized. Methods of treating a bone deficiency or fracture making use of such compositions are also described.

## Claims

### Claim 1

A bone graft composition, comprising:
(a) from 1 to 90 percent by weight keratose;
(b) from 1 to 90 percent by weight kerateine;
(c) optionally, from 1 to 90 percent by weight particulate filler;
(d) optionally, from 0.001 to 5 percent by weight antibiotic; and
(e) water or saline to balance.

### Claim 2 (depends on 1)

The composition of claim 1, wherein said composition is a nonwoven mesh, sponge, or hydrogel.

### Claim 3 (depends on 1)

The composition of claim 1, wherein said keratose is alpha/KAP keratose, gamma keratose, or mixtures thereof.

### Claim 4 (depends on 1)

The composition of claim 1, wherein said kerateine is alpha/KAP kerateine, gamma kerateine, or mixtures thereof.

### Claim 5 (depends on 1)

The composition of claim 1, wherein said composition comprises from 10 to 90 percent by weight keratose and from 90 to 10 percent by weight kerateine.

### Claim 6 (depends on 1)

The composition of claim 1, wherein said composition comprises from 1 to 30 percent by weight keratose and from 1 to 30 percent by weight kerateine.

### Claim 7 (depends on 1)

The composition of claim 1, further comprising from 0.001 to 5 percent by weight bone morphogenetic protein 2 (BMP2).

### Claim 8 (depends on 1)

The composition of claim 1, wherein said composition comprises a particulate filler selected from the group consisting of tetracalcium phosphate, tricalcium phosphate, calcium alkali phosphate ceramic, bioglass, calcium carbonate, calcium hydroxide, calcium oxide, calcium fluoride, calcium sulfate, magnesium hydroxide, hydroxyapatite, calcium phosphorus apatite, magnesium oxide, magnesium carbonate, magnesium fluoride, collagen, and mixtures thereof.

### Claim 9 (depends on 1)

The composition of claim 1, wherein said composition comprises a particulate filler selected from the group consisting of hydroxyapatite, tricalcium phosphate, or a mixture thereof.

### Claim 10 (depends on 1)

The composition of claim 1, wherein said antibiotic is selected from the group consisting of cefazolin, vancomycin, gentamycin, erythromycin, bacitracin, neomycin, penicillin, polymycin B, tetracycline, biomycin, chloromycetin, streptomycin, ampicillin, azactam, tobramycin, clindamycin, gentamicin, and combinations thereof.

### Claim 11 (depends on 1)

The composition of claim 1, wherein said composition is sterile.

### Claim 12 (depends on 11)

The composition of claim 11 packaged in a sterile container.

### Claim 13 (depends on 1)

A lyophilized or freeze-dried composition which upon reconstitution with water or saline solution produces a composition of claim 1.

### Claim 14 (depends on 1)

The composition of claim 1, further comprising stem cells.

### Claim 15 (depends on 14)

The composition of claim 14, wherein said stem cells are mesenchymal stem cells.

### Claim 16 (depends on 15)

The composition of claim 15, wherein said mesenchymal stem cells are harvested from bone marrow or adipose tissue.

### Claim 17 (depends on 14)

The composition of claim 14, wherein said cells are adipose derived stem cells.

### Claim 18 (depends on 14)

The composition of claim 14, wherein said cells are collected from a human subject who is at least 40 years old at the time of harvest.

### Claim 19 (depends on 1)

A method of treating a bone deficiency in a subject in need thereof, comprising administering the composition of claim 1 to said subject in a treatment effective amount.

### Claim 20 (depends on 19)

The method of claim 19, wherein said subject is an osteoporotic or osteopenic subject.

### Claim 21 (depends on 14, 19)

The method of claim 19, wherein said method comprises administering the composition of claim 14, wherein said stem cells are autologous.

### Claim 22 (depends on 19)

The method of claim 19, wherein said administering comprises injecting.

### Claim 23 (depends on 1)

A method of treating a fracture in a subject in need thereof, comprising contacting a composition of claim 1 to said fracture in a treatment-effective amount.
